United Story

The company reported the previous year's revenue of 1.41 B. Net Income was 468.6 M with profit before overhead, payroll, taxes, and interest of 1.33 B.

	2018	2020	2021 (projected)
PPandE Turnover	2.61	1.81	2.04
Calculated Tax Rate	22.36	20.13	24.52

Cost of Revenue Breakdown

United Therapeutic Cost of Revenue yearly trend continues to be relatively stable with very little volatility. Cost of Revenue is likely to drop to about 56 M. Cost of Revenue usually refers to the aggregate cost of goods produced and sold and services rendered during the reporting period. United Therapeutic Cost of Revenue is relatively stable at the moment as compared to the past year. United Therapeutic reported last year Cost of Revenue of 65.43 Million

	2011	88.9 Million
	2012	119.3 Million
	2013	131.13 Million
	2014	125.9 Million
	2015	69 Million
	2016	72.7 Million
	2020	65.43 Million
	2021	56.04 Million

How will United retail investors react to the next fall?

Coefficient of variation is down to 614.91. It may connote a possible volatility fall. United Therapeutic has relatively low volatility with skewness of 0.12 and kurtosis of 0.41. However, we advise all investors to independently investigate United Therapeutic to ensure all accessible information is consistent with the expectations about its upside potential and future expected returns. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure United Therapeutic's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact United Therapeutic's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Our Takeaway on United Therapeutic Investment

While some firms in the biotechnology industry are either recovering or due for a correction, United Therapeutic may not be performing as strong as the other in terms of long-term growth potentials. The bottom line, as of the 24th of February 2021, our research shows that United Therapeutic is a rather very steady investment opportunity with a low chance of financial distress in the next two years. From a slightly different view, the entity currently appears to be undervalued. Our ongoing 30 days buy-or-sell advice on the enterprise is Strong Buy.